MS4a4B, a CD20 homologue in T cells, inhibits T cell propagation by modulation of cell cycle.

Hui Xu  
*Department of Neurology, Thomas Jefferson University, Philadelphia, PA*

Yaping Yan  
*Department of Neurology, Thomas Jefferson University, Philadelphia, PA*

Mark S Williams  
*Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD*

Gregory B Carey  
*Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD*

Jingxian Yang  
*Department of Neurology, Thomas Jefferson University, Philadelphia, PA*

Follow this and additional works at: [https://jdc.jefferson.edu/neurologyfp](https://jdc.jefferson.edu/neurologyfp)

Let us know how access to this document benefits you  
See next page for additional authors

**Recommended Citation**

Xu, Hui; Yan, Yaping; Williams, Mark S; Carey, Gregory B; Yang, Jingxian; Li, Hongmei; Zhang, Guang-Xian; and Rostami, Abdolmohamad, "MS4a4B, a CD20 homologue in T cells, inhibits T cell propagation by modulation of cell cycle." (2010). *Department of Neurology Faculty Papers*. Paper 43.  
[https://jdc.jefferson.edu/neurologyfp/43](https://jdc.jefferson.edu/neurologyfp/43)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning (CTL)](https://jefferson.edu/ctl). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
MS4a4B, a CD20 Homologue in T Cells, Inhibits T Cell Propagation by Modulation of Cell Cycle

Hui Xu1, Yaping Yan1, Mark S. Williams2, Gregory B. Carey2, Jingxian Yang1, Hongmei Li1, Guang-Xian Zhang1, Abdolmohamad Rostami1

1Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America, 2Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

Introduction

MS4a4B is a novel member of the MS4A gene family (membrane-spanning 4-domain family, subfamily A, MS4As) which is characterized by their structural features, with four membrane-spanning domains, two extracellular domains and two cytoplasmic regions [1]. The MS4A family includes CD20, FcγRIIB, HTm4 and at least 26 novel members that are characterized by their structural features: with four membrane-spanning domains, two extracellular domains and two cytoplasmic regions. CD20, FcγRIIB and HTm4 have been found to function in B cells, mast cells and hematopoietic cells respectively. However, little is known about the function of MS4a4B in T cell regulation. We demonstrate here that MS4a4B negatively regulates mouse T cell proliferation. MS4a4B is highly expressed in primary T cells, natural killer cells (NK) and some T cell lines. But its expression in all malignant T cells, including thymoma and T hybridoma tested, was silenced. Interestingly, its expression was regulated during T cell activation. Viral vector-driven overexpression of MS4a4B in primary T cells and EL4 thymoma cells reduced cell proliferation. In contrast, knockdown of MS4a4B accelerated T cell proliferation. Cell cycle analysis showed that MS4a4B regulated T cell proliferation by inhibiting entry of the cells into S-G2/M phase. MS4a4B-mediated inhibition of cell cycle was correlated with upregulation of Cdk inhibitory proteins and decreased levels of Cdk2 activity, subsequently leading to inhibition of cell cycle progression. Our data indicate that MS4a4B negatively regulates T cell proliferation. MS4a4B, therefore, may serve as a modulator in the negative-feedback regulatory loop of activated T cells.
inhibits the G1-S transition of cell cycle through interaction with cyclin-dependent kinase-associated (CDK-associated) phosphatase-CDK2 (KAP-CDK2) complexes [15,24]. It remains unclear whether other members of the MS4A family, including MS4a4B, play roles in cell cycle and cell proliferation. Given that CD20 is critical for cell proliferation and cell cycle regulation in B cells, and serves as a target for anti-CD20-based immune therapeutics of B cell-related diseases [25] we are encouraged to dissect the biological function of MS4a4B in T cells.

In this report, we demonstrate that although MS4a4B is expressed at high levels in mature T cells, its expression is silenced in malignant T cells. We analyzed the impact of MS4a4B on T cell proliferation by manipulating MS4a4B expression with MS4a4B-expressing and -silencing approaches. We found that MS4a4B negatively regulates T cell proliferation by interfering with cell cycle progression from G0/G1 phase into S-G2/M phases through inhibition of the Cd2k-Rb pathway, and that silence of MS4a4B in thymoma is, at least partially, responsible for the uncontrollable propagation of tumor T cells.

Results

MS4a4B is expressed in mature T cells but not in malignant T cells

To define the expression of MS4a4B, we detected MS4a4B protein in mouse cells, including normal T cells, non-T cells, and malignant T cells, by using anti-MS4a4B antibodies and flow cytometric analysis. Consistent with our previous findings [1], MS4a4B was strongly expressed in naive T cells but was not expressed in B cells. In addition to T cells, we also examined expression of MS4a4B in other cells. The results showed that MS4a4B was also expressed at high levels in NK cells (marked by NK1.1) and moderately expressed in macrophages (marked by Mac1) (supplementary Fig. S1A). In bone marrow cells, only the Mac1+ population expressed low levels of MS4a4B, suggesting MS4a4B expression in early hematopoietic progenitors (supplementary Fig. S1A). Surprisingly, all malignant T cells, including thymoma and T hybridoma cell lines that we have examined so far, lose expression of MS4a4B (Table 1 and supplementary Fig. S2). Lack of MS4a4B protein in thymoma cells led us to postulate that MS4a4B may be required for appropriate functioning of mature T cells and the absence of this protein may be, at least in part, responsible for the uncontrollable growth of thymoma. Western blotting with surface-biotin labeling of primary T cells and histological studies with confocal microscopy of MS4a4B-expressing retrovirus-infected EL4 thymoma cells showed that MS4a4B was indeed expressed on cell surface (Fig. 1A and B), suggesting that MS4a4B may potentially interact with other cell membrane proteins in T cell regulation. Interestingly, expression of MS4a4B is regulated not only during thymocyte development [1] but also during primary T cell activation (Fig. 1C). Although MS4a4B was constitutively expressed in primary naive T cells, levels of its expression were markedly increased upon stimulation by mitogen concanavalin A (Con A). However, expression of MS4a4B was gradually decreased by 72 hour of activation. It is of note that the down-regulation of MS4a4B was closely associated with reduction of surface CD3 expression in T cells (Fig. 1D), which led us to speculate whether this CD3low/MS4a4Blow population might represent the cells undergoing apoptosis. We further examined apoptosis of this population by Annexin V assay. The CD3low/MS4a4Blow population showed markedly high levels of apoptotic cells (Fig. 1E). Thus, temporal expression of MS4a4B in activated T cells and silence of the MS4a4B gene in malignant T cells led us to hypothesize that MS4a4B may play a regulatory role in propagation of T cells.

Inhibitory role of MS4a4B in T cell proliferation

T cell proliferation is a critical process for T cell-mediated immunity, which is reciprocally regulated at multiple levels by numerous activators and inhibitors [26,27,28]. Its regulation, however, is still not clearly understood. Studies on CD20 suggest that MS4A proteins may regulate cell proliferation [13,23]. To determine the role of MS4a4B in T cell proliferation, we constructed a MS4a4B-expressing retroviral vector, which co-expresses GFP as a selection marker. We used the MS4a4B-retroviral vector to manipulate expression of MS4a4B in primary T cells, which were subsequently labeled with PHK-26, a red fluorescent dye, and analyzed T cell proliferation upon CD3/CD28 stimulation by flow cytometry. Over-expression of MS4a4B by retroviral vector indeed inhibited proliferation of primary T cells (Fig. 2A). Since primary T cells constitutively expressed high levels of MS4a4B, we next used EL4 cells (MS4a4B-), a widely used thymoma cell line [29,30,31], to confirm the inhibitory effect of MS4a4B on T cell proliferation. We constructed a lentiviral vector (LV) to express MS4a4B and a GFP marker in EL4 cells. To test proliferation of EL4 cells, the infected EL4 cells were labeled with PHK-26 and cell proliferation was analyzed.

Table 1. Expression of MS4a4B in mouse T cells and non-T cells.

| Primary T cell | T cell line | Malignant T cell | Non-T cell |
|---------------|-------------|-----------------|------------|
| Cell          | MS4a4B      | Cell            | MS4a4B     | Cell          | MS4a4B |
| CD4\(^+\)     | +++\(^*\)   | T32\(+++\)     | EL4\(\_\)  | B cell\(\_\) |
| CD8\(^+\)     | +++         | AE7\(+++\)     | TIB84\(\_\) | NK\(+++\)    |
| NKT           | +++         | SCC7\(+++\)    | CRL1778\(\_\) | Bone marrow\(\_\) |
| NKT           | +++         | HT2 (\_\_\_)   | 2993\(\_\) | Macrophage\(\_\) |
| NKT           | +++         | CTLL\(\_\_\_)  | T-180\(\_\) | \_\_\_ |
| NKT           | +++         | S8\(\_\)       | \_\_\_     | \_\_\_ |
| NKT           | +++         | n2B\(\_\)      | \_\_\_     | \_\_\_ |

\(^*\)MS4a4B expression was determined by flow cytometric analysis with anti-MS4a4B intracellular staining. Negative is indicated as \(\_\_\_\); positive is indicated by expression levels based on fluorescent intensity as low (\(\_\_\_\)), middle (\(\_\_\_\)) and high (\(+++\)).

\(^*\)EL4, TIB84, CRL1778, 2993 and T180 are thymoma cell lines; S8x and n2B cells are T hybridoma.

doi:10.1371/journal.pone.0013780.t001
Figure 1. MS4a4B is expressed on cell surface and is potentially associated with activation of T cells. A, To determine whether MS4a4B is expressed on cell surface, mouse spleen cells were surface-labeled with EZ-Link Sulfo-NHS-SS-Biotin according to the manufacturer’s protocol (Pierce). Unlabeled spleen cells were used as control. Cells were lysed by lysis buffer containing 1% NP-40. Cell lysate was immunoprecipitated by anti-MS4a4B-coupled protein A-beads and was separated on 12% SDS-PAGE, followed by blotting with streptavidin-HRP. MS4a4B was confirmed by re-blotting with anti-MS4a4B antibody. B, EL4 cells, infected with either MS4a4B-expressing lentivirus (LV) vector or mock LV vector, were stained with rabbit anti-MS4a4B antibody followed by labeling with anti-rabbit-IgG-Cy3 conjugate. Expression and localization of MS4a4B were observed by confocal microscopy. Magnification, ×40. C, Spleen cells were cultured for 24, 48 and 72 hrs in the presence or absence of Con A (5 μg/ml). Spleen cells before culture were used as control (0 hr). Cells were first stained with anti-CD3-PE, and then intracellular stained with biotinylated anti-MS4a4B.
by flow cytometry. As predicted, forced expression of MS4a4B inhibited EL4 thymoma cell proliferation (Fig. 2B).

Small interfering RNA (siRNA)-mediated gene silencing has been shown to be a powerful approach for studying protein function [32]. Since forced expression of MS4a4B overphysiologic levels in cells may lead to artificial data interpretation in some cases, we next proceeded to knockdown MS4a4B expression. To confirm the inhibitory role of MS4a4B in T cell propagation, we used synthetized siRNAs to silence expression of MS4a4B in T32 cells, a T helper cell line derived from normal primary T cells, which normally expresses high levels of MS4a4B protein [1]. Three siRNA duplexes were designed to target cDNA regions encoding the N-terminal region, the first extracellular domain, and the C-terminal intracellular domain of MS4a4B respectively (supplementary Fig. S3A and B). Knockdown of MS4a4B by selected MS4a4B-siRNAs markedly reduced expression of MS4a4B at both RNA transcription and protein levels (Fig. 2C, 2D and Supplementary Fig. S3C). In comparison with RNA expression, siRNA-induced reduction of MS4a4B protein was somewhat delayed, perhaps due to the longer half-life of protein. To determine the impact of MS4a4B knockdown on cell proliferation, T32 cells pre-labeled with PHK-26 were transfected with FAM-labeled either MS4a4B-specific siRNA (siMS4a4B2) or negative control siRNA. Proliferation of the transfected cells in culture was assessed by flow cytometry. Consistent with the findings from over-expression studies, knockdown of MS4a4B accelerated proliferation of T32 cells (Fig. 2E). Similar results were observed in primary T cells from C57BL/6 mice when MS4a4B expression was knocked down by siRNA approaches (Fig. 2F), suggesting that MS4a4B plays an inhibitory role in T cell propagation. This appears not to be in line with our previous observation in which overexpression of MS4a4B enhanced IL-2 levels in activated T cells. It remains to be elucidated whether MS4a4B plays a role in survival of differentiated Th1 cells, which lead to a prolonged IL-2 production in these cells. To test how MS4a4B expression impacts IL-2 responsiveness of T cells, we added serially diluted IL-2 in culture of T32 cells transfected with either shMS4a4B lentiviruses (for MS4a4B knockdown) or shLuc lentiviral vector as control and analyzed proliferation of these cells. The results showed that knockdown of MS4a4B accelerated IL-2-induced proliferation of T32 cells (Fig. 2G).

To confirm if MS4a4B does serve as a negative modulator for T cell proliferation in vivo, EL4 cells infected with either MS4a4B-expressing-lentivirus or mock control lentiviral vector were infected into C57BL/6 mice recipients. EL4 cell propagation was analyzed by the percentage of infected EL4 cells in blood and spleen with flow cytometry three days after cell transfer. As indicated by the percentage of GFP-positive cells, MS4a4B-expression reduced the propagation of EL4 cells in both peripheral blood (Fig 3A and B) and spleens (Fig. 3C and D). To exclude the possibility that MS4a4B-infected EL4 cells may dominantly migrate into organs other than spleen, we also examined brain, thymus, heart, lung, liver, kidney and intestine. The results showed that there were no infected EL4 cells (GFP+) detected in those organs except heart and liver, in which the level of MS4a4B-infected EL4 cells was also slightly lower than that of LV-infected EL4 cells (data not shown). To further verify the inhibitory role of MS4a4B in solid thymoma, 1x10^6 MS4a4B-expressing lentivirus (or control vector)-infected EL4 cells were inoculated subcutaneously in the right flank of 8–10 week-old C57BL/6 mice. Tumor growth was monitored daily after inoculation. Results showed that forced expression of MS4a4B in EL4 cells significantly reduced tumor growth in vivo (P<0.001) (Fig. 3E). This is unlikely due to host specific cellular responses to MS4a4B protein given that spleen cells from EL4-inoculated hosts did not respond to EL4 cells expressing MS4a4B when they were cocultured with EL4-MS4a4B cells in vitro (data not shown).

**MS4a4B regulates T cell proliferation by interfering cell cycle progression**

It has been documented that CD20 regulates B cell proliferation by impacting cell cycle progression in these cells [22,23]. HTm4 was found to prevent cell cycle progression from G0/G1 phase into S-G2/M phase in hematopoietic cells [15,24]. To get some insight into how MS4a4B modulates T cell proliferation, we tested if MS4a4B protein regulates cell cycle progression by using MS4a4B-lentivirus-infected EL4 cells. EL4 cells stably infected by MS4a4B-lentivirus (or mock lentiviral vector as control) were synchronized as described before and analyzed by flow cytometry with propidium iodide staining. After 8 hours of stimulation, 68.5% of control cells entered S-G2/M phase. In contrast, the percentage of cells that entered S-G2/M phase was markedly reduced in MS4a4B-expressing vector-infected EL4 cells (Fig. 4A). These results suggest that MS4a4B protein inhibits cell proliferation by preventing cell cycle progression from G0/G1 phase into S-G2/M phases.

To further confirm the role of MS4a4B in cell cycle regulation by knockdown approaches, we constructed a lentiviral vector expressing short hairpin RNA (shRNA) for MS4a4B (MS4a4B-shRNA), which was designed based on the targeting sequence (siMS4a4B2) selected by siRNA knockdown experiments described above. Knockdown by MS4a4B-shRNA vector markedly reduced MS4a4B mRNA (supplementary Fig. S4) and protein expression (Fig. 4B and C). To determine the impact of MS4a4B-knockdown on cell cycle, shRNA-targeting vector-infected T32 cells were isolated by flow cytometric cell sorting to achieve >99% of GFP expression. The purified T32 cells were synchronized as described for EL4 cells above. The cells then were stimulated by complete medium containing 15% FCS. Cell samples from culture were analyzed for cell cycle by propidium iodide staining and flow cytometric analysis. Consistent with the observation from overexpression experiments, knockdown of MS4a4B protein promoted cell cycle progression from G0/G1 phase into S-G2/M phase (Fig. 4D), indicating that reduction of MS4a4B protein released cells from MS4a4B-mediated suppression of cell cycle.

**MS4a4B-mediated cell cycle inhibition is correlated with enhanced expression of cell cycle inhibitors and reduced Cdk2 activity**

Cell cycle progression is driven by the temporal induction and activation of cyclin-dependent kinases (CDKs) [34]. Activation of CDKs requires the formation of CDK-cyclin complexes and is
Figure 2. MS4a4B negatively regulates T cell proliferation. A, Retrovirus-driven over-expression of MS4a4B inhibits proliferation of primary T cells. Primary CD4+ T cells isolated from spleen with anti-CD4 magnetic beads were stimulated by anti-CD3/anti-CD28 antibodies and then were infected with MS4a4B-retroviral vector or mock vector. After infection, cells were labeled with PKH-26 Red Fluorescent linker kit. Proliferation of the tested cells was analyzed by flow cytometry (FL2). Data shown are representative of three repeat experiments.

B, Forced expression of MS4a4B by LV-vector reduced proliferation of EL4 cells. Purified EL4 cells with stable lentiviral infection were labeled with PKH-26 Red and then cultured in complete RPMI 1640 medium. Cells were collected on the days indicated. Cell proliferation was assessed by flow cytometry. Data shown are representative of three repeat experiments. The numbers in histograms are mean fluorescence intensity (MFI)

C, Knockdown of MS4a4B by siRNA. T32 cells were transfected with either FAM-labeled negative control siRNA or FAM-labeled MS4a4B-specific siRNAs (siMS4a4B1 and siMS4a4B2). Cells

---

**Figure 2. MS4a4B negatively regulates T cell proliferation.**

A, Retrovirus-driven over-expression of MS4a4B inhibits proliferation of primary T cells. Primary CD4+ T cells isolated from spleen with anti-CD4 magnetic beads were stimulated by anti-CD3/anti-CD28 antibodies and then were infected with MS4a4B-retroviral vector or mock vector. After infection, cells were labeled with PKH-26 Red Fluorescent linker kit. Proliferation of the tested cells was analyzed by flow cytometry (FL2). Data shown are representative of three repeat experiments.

B, Forced expression of MS4a4B by LV-vector reduced proliferation of EL4 cells. Purified EL4 cells with stable lentiviral infection were labeled with PKH-26 Red and then cultured in complete RPMI 1640 medium. Cells were collected on the days indicated. Cell proliferation was assessed by flow cytometry. Data shown are representative of three repeat experiments. The numbers in histograms are mean fluorescence intensity (MFI). ***, p < 0.001.

C, Knockdown of MS4a4B by siRNA. T32 cells were transfected with either FAM-labeled negative control siRNA or FAM-labeled MS4a4B-specific siRNAs (siMS4a4B1 and siMS4a4B2). Cells
were collected on day 3 after transfection. Transcription of MS4a4B mRNA was analyzed by RT-PCR. D, Cell samples collected from culture on day 4 were subjected to MS4a4B protein detection by flow cytometry with anti-MS4a4B antibody. Data are presented as fluorescence intensity of FL-2 in FAM-positive population. Blue line: siMS4a4B2-transfected cells; red line: control siRNA-transfected cells. E and F, Knockdown of MS4a4B expression accelerated proliferation of T32 cells (E) and primary T cells (F). T32 cells or anti-CD3/anti-CD28-stimulated CD4+ primary T cells were labeled with PKH-26 Red and were transfected with FAM-labeled negative control siRNA or FAM-labeled siMS4a4B2. The labeled cells were stimulated with complete medium containing 20 U/ml IL-2. Cells were collected from culture at the time indicated for determination of proliferation rate by flow cytometric analysis. Data are presented as representative of three repeat experiments. Tinted grey peak: unlabeled cells; blue line: siMS4a4B2-transfected cells; red line: control siRNA-transfected cells. The numbers in histograms are MFI ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. G, Knockdown of MS4a4B accelerated IL-2-induced proliferation of T32 cells. T32 cells were infected with either shMS4a4B- or shLuc-lentiviral vector. Infected cells (1 × 10^5) were cultured in 96 well plate for 24 hr in the presence of serially diluted IL-2, followed by incubation with 1μg CH3-thymidine for an additional 16 hr. Cell proliferation was assayed by 3H-thymidine incorporation. A representative of two independent experiments is shown. *, p < 0.05; **, p < 0.01. doi:10.1371/journal.pone.0013780.g002

Discussion

It has been shown previously that MS4a4B is selectively expressed in Th1 cells [1,20] and regulatory T cells [Treg] [19]. In primary T cells, MS4a4B is associated with Th1-cytokine production and its expression is repressed by Stat6-signaling [20]. In Treg cells, interaction of MS4a4B with GITR augments GITR signaling and T cell IL-2 production [19]. In this study, we demonstrated, for the first time, that MS4a4B plays an inhibitory role in T cell proliferation. Although MS4a4B is highly expressed in mature primary T cells, it is absent in malignant T cells. Interestingly, MS4a4B expression is upregulated during activation of primary T cells and overexpression of MS4a4B by viral vectors downregulates T cell proliferation, suggesting that MS4a4B may serve as “survival modulator” to protect activated cells from overgrowth. On the other hand, silence of MS4a4B in thymoma and T hybridoma cells may partially explain the uncontrollable growth of malignant T cells. Absence of MS4a4B expression in thymoma cells is likely due to active suppression of MS4a4B gene transcription by unknown factors derived from tumor cells rather than mutation of the MS4a4B gene itself since T hybridoma cells also lose MS4a4B expression (Table 1), in which MS4a4B gene should be compensated by the alleles from normal T cells. Of note, MS4a4B is also expressed at low levels in bone marrow cells. It is unclear whether this proportion of bone marrow cells represents the hematopoietic progenitors that have the potential to migrate into the thymus and are committed to T cell lineage.

CD20 and HTm4 have been shown to regulate proliferation of activated B cells and hematopoietic cells respectively by interfering with cell cycle progression [15,22]. Although the mechanisms underlying CD20 or HTm4-mediated regulations are not fully understood, available evidences support that they are using different mechanisms. CD20 is thought to be a regulator of transmembrane Ca2+ conductance which indirectly impacts cell cycle progression and proliferation of B cells [11,38]. Antibody binding to a CD20 epitope (B1) hence inhibits cell cycle progression of B cells [22]. HTm4 has been found to bind to cyclin-dependent kinase-associated (CDK-associated) phosphatase-CDK2 (KAP-CDK2) complexes by its C-terminal region and to stimulate the phosphatase activity of KAP, which subsequently causes cell cycle arrest at the G0/G1 phase. Cell membrane localization of MS4a4B protein in T cells is similar to that of CD20 in B cells but differs from that of HTm4, which is mainly localized on nuclear membrane [15]. It remains to be determined whether MS4a4B can serve as a calcium channel, or as a regulatory protein for cell receptor (as CD20 does in B cells [11,39]). In comparison with CD20, both MS4a4B and CD20 regulate cell cycle and cell proliferation. However, the effect of MS4a4B on cell cycle and cell proliferation in T cells seems different from that of CD20 in B cells since expression of recombinant CD20 was shown to accelerate cell cycle progression [21]. This difference may explain why B lymphoma cells conserve expression of CD20 while tumor T cells eliminate MS4a4B expression. In contrast, the inhibitory role of MS4a4B on cell cycle and cell proliferation is similar to that of HTm4 in hematopoietic cells, in which overexpression of HTm4 causes cell cycle arrest at

EGFP-positive population. Blue line: siMS4a4B2-transfected cells; red line: control siRNA-transfected cells. The numbers in histograms are MFI ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
the G0/G1 phase [15]. These data suggest that function of MS4A proteins may vary in different types of cells despite the homology in amino acid sequences and the similarity in structure among the MS4A gene family.

Data from our studies thus far show that MS4a4B inhibits cell cycle progression of T cells possibly by modulating levels of cell cycle regulatory elements. In primary T cells, CD4⁺ T cell line and thymoma cells, as confirmed by both overexpression and

**Figure 3. Expression of MS4a4B by lentiviral vector inhibits propagation of thymoma cells in vivo.** EL4 thymoma cells were infected by MS4a4B-LV or mock LV control. The infected cells (GFP⁺) were purified by flow cytometric cell sorting (purity: >99%). 1.5×10⁷ sorted cells were infused into C57BL/6J recipients by i.v injection. Mice were sacrificed on day 3 after cell transfer. EL4 thymoma cells (GFP⁺) in blood and spleen were assessed by flow cytometry. Data shown are representative of three repeat experiments. **A,** Representative flow histograms for each group of blood samples. The number shown is percentage of GFP⁺ cells in lymphocyte gate. **B,** Percentage ± SD of GFP⁺ cells in blood samples from mice injected with either MS4a4B-LV-infected or mock LV-infected EL4 cells (N = 5). **C,** Representative flow histograms for each group of spleen samples. The number shown is percentage of GFP⁺ cells in lymphocyte gate. **D,** Percentage ± SD of GFP⁺ cells in spleens from mice injected with either MS4a4B-LV-infected or mock LV-infected EL4 cells (N = 5). **E,** MS4a4B inhibits solid thymoma growth in vivo. 1×10⁶ EL4 cells were injected subcutaneously in the right flank of mice. Size of tumor was measured daily after inoculation. Results are presented as mean ± SD of mm² (N = 8). Data shown are representative of two independent repeat experiments.

doi:10.1371/journal.pone.0013780.g003
Figure 4. Expression of MS4a4B in T cells modulates cell cycle progression. A, MS4a4B-LV or mock LV-infected EL4 thymoma cells were synchronized by treatments with 2.5 mM thymidine and serum starvation. The synchronized cells were adjusted into 5×10³/ml and were stimulated with complete medium containing 15% FCS. For cell cycle analysis, cells were harvested from culture at the time indicated. DNA content in cells was determined by propidium iodide staining and flow cytometric analysis. Results are shown as histogram from each sample with numbers indicating DNA content.
knockdown approaches, MS4a4B is correlated with increase of cell
cycle inhibitors, e.g., p16
\textsuperscript{Ink4a}, p21
\textsuperscript{Cip1} and p27
\textsuperscript{Kip1}, and decrease of
cyclin A and B. Furthermore, overexpression of MS4a4B caused
reduction of Cdk2 activity and promoted dephosphorylation of Rb.
Cdk2 is a crucial molecule that drives cell cycle transition from G0/
G1 to S-G2/M phases [40]. Downregulation of Cdk2 activity will
therefore result in dephosphorylation of Rb, subsequently leading to
inhibition of gene transcription and cell cycle arrest. To date, we
have no data to show whether MS4a4B inhibits Cdk2 activity by
interacting with other regulatory molecules, e.g., KAP, as HTm4
does. However, evidences from our studies support the hypothesis
that MS4a4B more likely causes reduction of Cdk2 activity by

---

**Figure 5.** Expression of cell cycle-regulatory genes in MS4a4B-LV-infected EL4 cells. **A**, Total RNA was isolated from MS4a4B-LV vector- or
mock LV vector-infected EL4 cells. Expression of 84 key regulatory genes on cell cycle progression was determined with real time PCR array analysis kit
(Cat\#: PAMM-020, SABiosciences, Gaithersburg, MD). Data were analyzed with on-line analysis software according to the manufacturer’s instructions and
presented as scatter plot with fold change of genes. Red dot: genes increased by \(\geq 4\) fold; blue dot: genes decreased by \(\geq 4\) fold. **B**, Genes with fold
change \(\geq 4\) were shown as column figure. **C**, MS4a4B (or control) vector-infected EL4 cells were synchronized and stimulated with 15% FCS for 8 hours.
Cell lysates (100 \(\mu\)g) were immunoprecipitated with anti-Cdk2-protein A beads. Cdk2-cyclin activity was assayed as described in “Methods”. The same
samples (25 \(\mu\)g) were used for western blot with anti-\(\beta\)-actin antibody to ensure identical loading. Relative intensity (sample vs. LV control) is shown in
the lower panel. \(*, p<0.05\). **D**, Cell lysates described in “C” were separated on 10% SDS gel followed by western blotting with appropriate antibodies as
indicated. E. Relative intensity of blots in “D” (sample vs. internal control (\(\beta\)-actin)) was determined by densitometry. \(*, p<0.05\).

doi:10.1371/journal.pone.0013780.g005
impacting upstream of the signaling pathway since overexpression of MS4a4B in EL4 cells also increases CamKk2a production. It has been documented that activation of Camkk2a may regulate cell cycle in either a negative or positive manner under different circumstances [41,42]. In case of MS4a4B expression in EL4 cells, MS4a4B protein may facilitate the Ca\textsuperscript{2+}/CaM signaling pathway by impacting intracellular Ca\textsuperscript{2+} activity and cause upregulation of Camkk2a, which promotes the transcription of Ink4 and Cip/Kip family Cdk inhibitors. Although machinery interplays in these processes still remain to be elucidated in detail, our data suggest that MS4a4B may modulate cell cycle transition by upregulation of cell cycle inhibitors and down-regulation of cell cycle activators possibly through the Ca\textsuperscript{2+}/CaM signaling pathway.

Cell proliferation and differentiation are two closely related but independent processes [43]. T cell activation and proliferation are essential for T cell differentiation [44]. Proliferating T cells usually have several fates under certain circumstances: toward terminal differentiation, or exit from cell cycle for resting and survival, or undergo apoptosis. It has been documented that TcR-stimulatory signals trigger T cell proliferation but preactivated T cells may undergo activation-induced cell death (AICD) in response to the same signals [45]. In our study, we found that MS4a4B expression was upregulated in activated T cells and decrease of MS4a4B was associated with apoptosis of T cells (Figure 1C and 1E). Given that MS4a4B can inhibit T cell proliferation, this raises the possibility that in addition to its anti-proliferative role, MS4a4B expression may prolong survival of activated T cells by preventing T cells from apoptosis. Currently, we have no evidence to show whether down-regulation of MS4a4B in apoptotic T cells is a cause or consequence of T cell apoptosis. If MS4a4B does have an anti-apoptotic effect and provide survival signals for activated T cells, that may explain why overexpression of MS4a4B in T cells enhanced IL-2 levels during T cell activation as we observed in our previous studies [1].

In conclusion, our study provides evidence that MS4a4B modulates T cell proliferation as a negative regulator by inhibiting cell cycle transition from G0/G1 phase into S-G2/M phase. Given that MS4a4B expression in primary T cells is upregulated after T cell activation, MS4a4B likely contributes to negative feedback regulatory pathways, which will self-limit over-propagation of activated T cells. In other words, it may facilitate activated T cells for long-term survival. This may account for its high levels of expression in mature T cells conserved by evolution. On the other hand, it may partially explain the uncontrollable growth of malignant T cells, e.g. thymoma. Since mature T cells express high levels of MS4a4B while malignant T cells lose its expression, MS4a4B may also serve as a biomarker to distinguish normal mature T cells from tumor T cells. Considering the structural and functional similarity between MS4a4B and CD20, as well as HTm4, this regulatory role of MS4a4B and other members of the MS4A gene family in cell proliferation could be fundamental for cellular biology in general. In addition, taking into count the importance of CD20 as a potential target on T cells for similar antibody-based therapeutic of T cell-mediated immune diseases.

Mice and cells
C57BL/6J mice, 8 to 10 weeks old, male (The Jackson Laboratory), were used for in vivo study and as donors for primary cells. EL4 and HEK 293T cells were from American Type Culture Collection (Manassas, VA). T cell clone T32 was obtained from D. Scott (University of Maryland School of Medicine). All cells were cultured with RPMI 1640 complete medium containing 10% of fetal calf serum (FCS) except for HEK 293T cells, which were cultured with DMEM complete medium containing 10% FCS.

Antibodies and immune staining
Antibodies used for immunostaining mouse cells were obtained from BD-Biosciences (San Diego, CA). Antibodies against C-terminal of MS4a4B were generated as described previously [1] and were biotinylated with SureLINK Chromogenic Biotin Labeling Kit (KPL, Gaithersburg, MD). MS4a4B intracellular staining was performed as described previously [1]. Flow cytometry was performed using a FACSCalibur (BD-Biosciences). Data were analyzed with FlowJo software (Tree Star, Ashland, OR).

Materials and Methods

Ethics Statement
All experiments were performed in accordance with National Institutes of Health and Thomas Jefferson University guidelines. The study involving vertebrate animals was approved by the Thomas Jefferson University Institutional Animal Care and Use Committee (IACUG, Protocol #835A).

Viral vectors for MS4a4B-overexpression
MS4a4B-GFP-MIGR retroviral vector was constructed as described previously [1]. MS4a4B-lentivirus vector was prepared by inserting MS4a4B-encoding sequence into a bicistronic lentiviral vector containing GFP marker [46]. The lentiviral vector particles were produced in HEK 293T packaging cells by using the three-plasmid transient transfection system [47].

Transfection and MS4a4B knockdown by siRNA
Three siRNA candidates were selected by using online siRNA design software to target different regions of the MS4a4B gene (supplementary Fig. S3). The synthesized siRNA duplexes were labeled with FAM at 5’-end of sense oligonucleotide of the duplex. FAM-labeled Silencer Negative Control #1 siRNA was purchased from Ambion, Applied Biosystems (Cat#:AM4611). Cell transfection was performed using Lipofectamine 2000 per the manufacturer’s protocol (Invitrogen). Knockdown efficiency was assessed
by flow cytometry with anti-MS4a4B antibodies and by RT-PCR with MS4a4B-specific primers [1].

Construction of MS4a4B-shRNA and Luc-shRNA-lentiviral vectors

Based on the knockdown efficiency of synthesized siMS4a4B duplexes, we selected encoding sequence 630–649 of MS4a4B (NCBI GenBank NM_021718) as target and shRNA for luciferase (Luc) as irrelevant control. MS4a4B-shRNA and Luc-shRNA fragments were synthesized by Sigma. shRNA-knockdown lentiviral vectors were constructed with a Gateway-based cloning system (Invitrogen). Briefly, selected shRNA fragments were inserted into pEN-mH1c entry vector (ATCC ID10326369) at AmH/Xml sites. Pol III-shRNA cassette from pEN-mH1c vector was in turn subcloned into pDSL-hpUGIH plasmid by LR recombination reaction to generate shRNA expression lentiviral vectors (supplementary Figure S4). For virus packaging, HEK 293T cells were transfected with pDSL-hpUGIH plasmid containing shRNA expression cassette by using the three-plasmid transient transfection system [47].

Viral infection of T cells

Primary T cell infection was performed as described previously [1]. Viral infection of T cell line and thymoma cells was performed as described for primary T cells except that there was no prestimulation.

Cell labeling and proliferation assay

T cell lines or primary T cells primed with either MS4a4B overexpression approach or MS4a4B-knockdown approach were labeled with PKH-26 red fluorescent dye (Sigma) according to the manufacturer’s instruction. Cell proliferation was measured by flow cytometry. To assess proliferation of MS4a4B virus or control vector-infected EL4 cells in vivo, 1.5 × 10^7 cells were infused into C57BL/6J recipient mice. Blood and spleen samples were harvested from mice on day 3 after cell transfer. Percentage of EL4 cells was determined by flow cytometry according to GFP expression.

Cell cycle analysis

EL4 cells stably infected with either MS4a4B expressing lentiviruses or mock vector were isolated by flow cytometric cell sorting (GFP expression >99%). Cells were then synchronized by two cycle treatments with 2.5 mM thymidine for 20 h (in complete medium containing 10% FCS for the first treatment and 0.5% FCS for the second treatment) with a 10-hour interval. Cells were collected from culture at serial time points. Cell cycle was analyzed by propidium iodide staining [48].

Cdk2 kinase assay

Cell lysates (100 μg) were immunoprecipitated with anti-CDK2-protein A beads. Immunoprecipitated protein was incubated at 30°C for 30 min with 2 μCi γ-P32-ATP and Histone H1 (Roche Diagnostics) as a substrate in kinase buffer (50 mM Hepes pH7.0, 10 mM MgCl2, 10 mM DTT) containing 30 μM ATP. The reaction was stopped by adding 2X sample buffer and boiled for 3 min before separation on a 12% SDS-PAGE. The gel was dried and exposed to X-ray film.

Statistical analysis

Statistical analysis was performed using a two-tailed t-test except EL4 solid tumor model, for which two-way ANOVA test was used to determine statistical difference between groups. A value of p < 0.05 is considered statistically significant.
References

1. Xu H, Williams MS, Spain LM (2006) Patterns of expression, membrane localization, and effects of ectopic expression suggest a function for Msh4/B, a CD20 homolog in T cell. Blood 107: 2400–2408.

2. Ishibashi K, Sunuki M, Sasaki S, Inui M (2001) Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and β subunit of the high-affinity IgE receptor. Gene 264: 87–93.

3. Liang Y, Tedder TF (2001) Identification of a CD20-, FcεRIβ-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 72: 119–127.

4. Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF (2001) Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics 53: 357–366.

5. Tedder TF, Disteche CM, Louie E, Adler DA, Croce CM, et al. (1989) The gene that encodes the human CD20 (B1) differentiation antigen is located on chromosome 11 near the t(11;14)(q13;q32) translocation site. J Immunol 142: 2555–2559.

6. Hupp K, Sivasuki D, Mock BA, Kinet JP (1989) Gene mapping of the three subunits of the high affinity FcR for IgE to mouse chromosomes 1 and 9. J Immunol 143: 3707–3719.

7. Tedder TF, Klejman G, Disteche CM, Adler DA, Schlossman SF, et al. (1988) Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. J Immunol 141: 4580–4594.

8. Stamenkovic I, Seed B (1988) Analysis of two cDNA clones encoding the B cell antigen, CD20, that is selectively expressed on B lymphocytes. J Exp Med 167: 1975–1980.

9. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF (1986) Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen receptor. J Immunol 143: 3787–3791.

10. Venkataraman C, Schaefer G, Schindler U (2000) Cutting edge: Chandra, a novel four-transmembrane domain protein differentially expressed in helper type 1 lymphocytes. J Immunol 165: 632–636.

11. Dayde T, Terrant E, Osheress M, Lerendel S, Penev S, et al. (2009) Tumor burden influences exposure and response to rituximab. Pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113: 3576–3572.

12. Takahashi Y, Rayman JB, Dynlacht BD (2000) Analysis of promotor binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14: 804–816.

13. Kues WA, Anger M, Carnwath JW, Paul D, Motlik J, et al. (2000) Cell cycle analysis of cyclin-dependent kinases (Cdk) and cyclin-dependent kinase (KAp,Cdk2) cyclin A complex enhances the phosphatase activity of KAp, dissociates cyclin A, and facilitates KAp dephosphorylation of Cdk2. J Biol Chem 275: 17235–17242.

14. Silverman GJ, Boyle DL (2008) Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 223: 175–185.

15. Green DR, Druin N, Pinkowski M (2003) Activation-induced death cell in T cells. Immunol Rev 193: 70–81.

16. Rubtsov YP, Rodensky AV (2007) TGF β-signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7: 443–453.

17. Thomson AW, Turner HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9: 324–337.

18. Arens R, Schepers K, Noire MA, van Oosterwijk MF, van Lieshout RA, et al. (2004) Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8 T cell function. J Exp Med 199: 1595–1605.

19. Halfteck GG, Elboim M, Gur C, Achdout H, Ghadihl H, et al. (2009) Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor Nkp46/NCR1. J Immunol 162: 2221–2230.

20. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498.

21. Golay JT, Clark EA, Beverley PC (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135: 3795–3801.

22. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153–166.

23. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699–2711.

24. Takahashi Y, Rayman JB, Dynlacht BD (2000) Analysis of promotor binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14: 804–816.